Skip to main content
BC Innovations
Feature Story

-Omics overdrive

G3 uses six kinds of -omics and more to find targets

By Karen Tkach, Staff Writer

Over the past five years, Global Genomics Group LLC (G3) has been steadily amassing and analyzing pan-omics data from 7,500 individuals for the identification and validation of biomarkers and therapeutic targets. Now, the company has validated its system in coronary artery disease, signed up Sanofi as its first pharma partner, and is on the hunt for more.

The deal was announced on Jan. 5, three days before G3 and its collaborator GNS Healthcare Inc. disclosed results from their GLOBAL clinical study, which was designed to identify biomarkers and targets associated with coronary artery disease (CAD).

Read Article
  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial

Management Updates

There were no items published for this section in the most recent issue. Click more >> to read previously published items.

Preclinical Results

There were no items published for this section in the most recent issue. Click more >> to read previously published items.